CELCUITY INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
CELCUITY INC. (CELC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-26
- CELCUITY INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.40%.
- CELCUITY INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.60%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -0.40% 10-K · filed 2026-03-26 |
| 2024-12-31 | -0.60% 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |